000009643 001__ 9643
000009643 005__ 20180208195229.0
000009643 0247_ $$2DOI$$a10.1149/1.3382944
000009643 0247_ $$2WOS$$aWOS:000277260200080
000009643 0247_ $$2ISSN$$a0013-4651
000009643 0247_ $$2ISSN$$a0096-4743
000009643 0247_ $$2ISSN$$a0096-4786
000009643 0247_ $$2ISSN$$a1945-7111
000009643 037__ $$aPreJuSER-9643
000009643 041__ $$aeng
000009643 082__ $$a540
000009643 084__ $$2WoS$$aElectrochemistry
000009643 084__ $$2WoS$$aMaterials Science, Coatings & Films
000009643 1001_ $$0P:(DE-Juel1)125595$$aHolländer, B.$$b0$$uFZJ
000009643 245__ $$aWet Chemical Etching of Si, Si1-xGex, and Ge in HF:H2O2:CH3COOH
000009643 260__ $$aPennington, NJ$$bElectrochemical Society$$c2010
000009643 300__ $$aH643 - H646
000009643 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article
000009643 3367_ $$2DataCite$$aOutput Types/Journal article
000009643 3367_ $$00$$2EndNote$$aJournal Article
000009643 3367_ $$2BibTeX$$aARTICLE
000009643 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000009643 3367_ $$2DRIVER$$aarticle
000009643 440_0 $$03889$$aJournal of the Electrochemical Society$$v157$$x0013-4651$$y6
000009643 500__ $$aThis work was supported by the European Commission, Information Society Technology (IST), within the framework of PULLNANO, contract no. IST-026828.
000009643 520__ $$aThis open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had previously completed a 12-week double-blind study.In total, 124 patients (aged 4-37 years), receiving 1-3 concomitant antiepileptic drugs, were treated with rufinamide approximately 25-60 mg/kg/day. Efficacy was assessed by seizure frequency; tolerability by adverse events (AEs) and laboratory tests.Overall, patients were treated with rufinamide for a median (range) of 432 (10-1149) days. Reductions in seizure frequency were observed throughout the study; during the last 12 months of treatment, 41.0% and 47.9% of patients had > or = 50% reduction in total and tonic-atonic seizure frequency, respectively. The most common AEs were vomiting (30.6%) and pyrexia (25.8%).In this open-label extension, rufinamide appeared to be an effective long-term adjunctive therapy for the treatment of LGS-associated seizures in children and young adults.
000009643 536__ $$0G:(DE-Juel1)FUEK412$$2G:(DE-HGF)$$aGrundlagen für zukünftige Informationstechnologien$$cP42$$x0
000009643 588__ $$aDataset connected to Web of Science, Pubmed
000009643 650_7 $$2WoSType$$aJ
000009643 7001_ $$0P:(DE-Juel1)125569$$aBuca, D.$$b1$$uFZJ
000009643 7001_ $$0P:(DE-Juel1)VDB4959$$aMantl, S.$$b2$$uFZJ
000009643 7001_ $$0P:(DE-HGF)0$$aHartmann, J.M.$$b3
000009643 773__ $$0PERI:(DE-600)2002179-3$$a10.1149/1.3382944$$gVol. 157, p. H643 - H646$$pH643 - H646$$q157<H643 - H646$$tJournal of the Electrochemical Society$$v157$$x0013-4651$$y2010
000009643 8567_ $$uhttp://dx.doi.org/10.1149/1.3382944
000009643 909CO $$ooai:juser.fz-juelich.de:9643$$pVDB
000009643 915__ $$0StatID:(DE-HGF)0010$$aJCR/ISI refereed
000009643 9141_ $$y2010
000009643 9131_ $$0G:(DE-Juel1)FUEK412$$aDE-HGF$$bSchlüsseltechnologien$$kP42$$lGrundlagen für zukünftige Informationstechnologien (FIT)$$vGrundlagen für zukünftige Informationstechnologien$$x0
000009643 9201_ $$0I:(DE-Juel1)VDB799$$d31.12.2010$$gIBN$$kIBN-1$$lHalbleiter-Nanoelektronik$$x0
000009643 9201_ $$0I:(DE-82)080009_20140620$$gJARA$$kJARA-FIT$$lJülich-Aachen Research Alliance - Fundamentals of Future Information Technology$$x1
000009643 970__ $$aVDB:(DE-Juel1)119578
000009643 980__ $$aVDB
000009643 980__ $$aConvertedRecord
000009643 980__ $$ajournal
000009643 980__ $$aI:(DE-Juel1)PGI-9-20110106
000009643 980__ $$aI:(DE-82)080009_20140620
000009643 980__ $$aUNRESTRICTED
000009643 981__ $$aI:(DE-Juel1)PGI-9-20110106
000009643 981__ $$aI:(DE-Juel1)VDB881